新闻
PLSE
--
0.00%
--
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday morning saw 454 companies set new 52-week lows.
Benzinga · 01/18 15:59
Pulse biosciences expects preliminary 4Q and FY21 revenues below the consensus
Pulse Biosciences (NASDAQ:PLSE) preliminary unaudited FY21 revenue is expected to be in the range of $1.3M to $1.4M (consensus of $1.44M). 4Q preliminary unaudited revenue expected of approximately $750K (consensus of
Seekingalpha · 01/11 12:31
BRIEF-Pulse Biosciences Announces Preliminary Fourth Quarter And Full Year 2021 Financial And Operational Results
reuters.com · 01/11 12:06
Destra Investment Trust 收购 ThredUp Inc、Etsy Inc、Riskified、出售、2U Inc
Investment company Destra Investment Trust (Current Portfolio) buys ThredUp Inc, Etsy Inc, Riskified, Luxfer Holdings PLC, Spero Therapeutics Inc, sells , , 2U Inc, Euronet Worldwide Inc, Sapiens International Corp NV during the 3-months ended 2021Q3, acco...
GuruFocus.com · 2021/12/28 07:38
What Type Of Shareholders Own The Most Number of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
The big shareholder groups in Pulse Biosciences, Inc. ( NASDAQ:PLSE ) have power over the company. Institutions often...
Simply Wall St. · 2021/12/17 14:20
Pulse Biosciences, Inc (PLSE)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks · 2021/11/25 15:00
Pulse Biosciences 将参加 Stephens 年度投资会议
HAYWARD, Calif., November 18, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the Stephens A...
Business Wire · 2021/11/18 21:05
HC Wainwright & Co. Maintains Buy on Pulse Biosciences, Lowers Price Target to $43
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and lowers the price target from $46 to $43.
Benzinga · 2021/11/16 14:12
Pulse Biosciences Q3 EPS $(0.48) Beats $(0.53) Estimate, Sales $574.00K Beat $190.00K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 5.88 percent increase over losses of $(0.51) per share from
Benzinga · 2021/11/15 22:27
Pulse Biosciences 每股收益超过 0.05 美元,收入超过
Pulse Biosciences (NASDAQ:PLSE): Q3 GAAP EPS of -$0.48 beats by $0.05. Revenue of $574M beats by $573.81M. Press Release
Seekingalpha · 2021/11/15 21:25
Pulse Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference
HAYWARD, Calif., November 04, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that members of management will present at...
Business Wire · 2021/11/04 20:05
Pulse Biosciences 任命 Laureen DeBuono 为董事会成员
HAYWARD, Calif., October 05, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Laureen DeBuono to i...
Business Wire · 2021/10/05 12:00
Brief-Pulse Biosciences 出售证券持有人可能要约或出售 300 万股
reuters.com · 2021/09/03 21:31
Pulse Biosciences 将参加 HC Wainwright 全球投资会议
HAYWARD, Calif., September 02, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the upcoming virt...
Business Wire · 2021/09/02 20:05
Pulse Biosciences(纳斯达克股票代码:PLSE)是否受到其债务负担的影响?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 2021/09/02 16:43
Pulse Biosciences 任命 Mitchell Levinson 为首席战略官
MT Newswires · 2021/08/19 16:41
Pulse Biosciences 第二季度每股收益 $(0.58) 超过 $(0.75) 估计
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.75) by 22.67 percent. This is a 9.43 percent decrease over losses of $(0.53) per share from
Benzinga · 2021/08/09 21:23
BRIEF-Pulse Biosciences Posts Quarterly Loss Per Share Of $0.58
reuters.com · 2021/08/09 20:52
-- 盈利快报 (PLSE) PULSE BIOSCIENCES 报告第二季度亏损 -0.58 美元,而 Street Est 为 -0.52 美元
MT Newswires · 2021/08/09 16:21
生物技术的未来一周(8 月 8 日至 14 日):Jazz Pharma FDA 的决定、收益泛滥和 IPO 成为焦点
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 2021/08/08 14:03
微牛提供丰富的实时PLSE股票新闻,让你可以通过多个平台了解PLSE股票行情最新动态,这些免费的脉冲生物科学新闻可以帮助你做出明智投资。
PLSE 简况
Pulse Biosciences Inc是一家新型生物电医药公司。该公司的纳米脉冲刺激(NPS)技术平台旨在向细胞发送能量脉冲,以在不破坏细胞外组织的情况下改变内部细胞器(包括线粒体和内质网)的功能。其商业产品“CellFX系统”被设计用来在非热作用机制的基础上,在NPS脉冲与细胞物理结构相互作用的可调速度和幅度引起的生物物理破坏中发挥作用。“CellFX系统”包括一个多用途手持件和五个一次性皮肤科治疗头的初始套件。